Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Data
Ashvattha Therapeutics announced it will present new data focusing on previously reported phase 2 clinical data on migaldendranib, its investigational subcutaneous therapy for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), which could offer a more convenient alternative to current injection-based treatments. Migaldendranib has a novel mechanism of action involving normalization of vascular endothelial growth factor (VEGF) expression in activated macrophage, microglia and retinal pigment epithelial cells.
The presentations will be made at 'Clinical Trials at the Summit,' June 21, 2025, in Las Vegas, and MaculArt, June 29-July 1, 2025 in Paris.
Clinical Trials at the Summit:
- Presentation Title: Subcutaneous Delivery of Migaldendranib: Twenty-four Week Results of a Phase 2 Study in DME and AMD
- Presentation Date/Time: Saturday, June 21, 2025; 9:01-9:05am PDT
- Session Type: Presentation
- Presenter: David Boyer, MD, Senior Partner, Retina-Vitreous Associates Medical Group and Adjunct Clinical Professor of Ophthalmology, University of Southern California/Keck School of Medicine
- Presentation Title: Emerging Technology: A Targeted, Novel, Nano-medicine that Normalizes VEGF Expression
- Presentation Date/Time: Saturday, June 21, 2025; 8:57-9:01am PDT
- Session Type: Presentation
- Presenter: Susan Schneider, MD, Retinal Ophthalmologist
- Presentation Title: Subcutaneous Migaldendranib (MGB) for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Interim Results of Chronic Dosing Phase 2 Study
- Presentation Date/Time: Sunday, June 29, 2025; 2:16-2:24pm CEST
- Session Type: Presentation
- Presenter: Michael Singer, MD, Clinical Professor of Ophthalmology, University of Texas Health Science Center San Antonio and Director of Clinical Research, Medical Center Ophthalmology San Antonio
Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells only in regions of inflammation. The targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care in ophthalmology.